<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: <z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> is a characteristic feature of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0001513'>obesity</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The present study examined the effects of TZD300512, a thiazolidinedione, on <z:chebi fb="105" ids="17234">glucose</z:chebi> and <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism in the fatty <z:chebi fb="3" ids="16646">Zucker</z:chebi> rat (fa/fa), a rat model of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: TZD300512 was administered (2.0 mg/kg/day) in the diet for 1 week to chronically catheterized <z:chebi fb="3" ids="16646">Zucker</z:chebi> fa/fa rats </plain></SENT>
<SENT sid="3" pm="."><plain>We measured <z:chebi fb="0" ids="17855">triglyceride</z:chebi> clearance rate and hepatic <z:chebi fb="0" ids="17855">triglyceride</z:chebi> output </plain></SENT>
<SENT sid="4" pm="."><plain>We assessed baseline <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism, and insulin-mediated <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake </plain></SENT>
<SENT sid="5" pm="."><plain>We also determined whether the insulin sensitivity enhancing effects of TZD300512 could be reversed by infusion of Intralipid </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: TZD300512 treatment markedly reduced fasting plasma <z:chebi fb="0" ids="17855">triglyceride</z:chebi> by 72% and nonesterified free fatty acids by 46% </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, treatment significantly enhanced plasma <z:chebi fb="0" ids="17855">triglyceride</z:chebi> clearance (AUC; 60.36+/-11.50 v 131.44+/-18.45 mM/min), but hepatic <z:chebi fb="0" ids="17855">triglyceride</z:chebi> output was not altered </plain></SENT>
<SENT sid="8" pm="."><plain>Drug treatment significantly reduced fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> by 25%, plasma insulin by 73%, and had no effect on glucagon levels </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="105" ids="17234">Glucose</z:chebi> infusion rate (GIR) needed to maintain euglycemia during hyperinsulinemic clamp was significantly increased from 34.96+/-3.94 micromol/kg/min to 123.80+/-4.80 micromol/kg/min, while whole body <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake was more than doubled (58.49+/-2.86 control vs. 126.97+/-3.8 treated micromol/kg/min) </plain></SENT>
<SENT sid="10" pm="."><plain>Insulin-induced suppression of hepatic <z:chebi fb="105" ids="17234">glucose</z:chebi> production was nearly complete with treatment </plain></SENT>
<SENT sid="11" pm="."><plain>Intralipid infusion reversed drug-induced improvement in insulin sensitivity </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: These results suggest that TZD300512-favourable alterations in <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism have a significant impact on its effectiveness in enhancing insulin sensitivity in a severely insulin resistant <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent model</z:e> of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>